FolateImmune therapy - Endocyte/Purdue University

Drug Profile

FolateImmune therapy - Endocyte/Purdue University

Alternative Names: Folate-conjugated vaccine - Endocyte

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Endocyte; Purdue University
  • Developer Endocyte
  • Class Cancer vaccines; Fluoresceins; Haptens; Imaging agents
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Renal cancer

Most Recent Events

  • 17 Dec 2013 Discontinued - Phase-I for Renal cancer in USA (SC)
  • 11 Feb 2009 The phase II trial is discontinued due to a lower than expected rate of accrual but phase I trials continue in renal cell carcinoma
  • 03 Jun 2008 Efficacy and adverse events data from a phase I trial in Renal cancer presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top